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Background: Chemotherapy has in some series been linked with increased morbidity after a hepatec-
tomy. Hepatic injuries may result from the treatment with chemotherapy, but can also be secondary to
co-morbid diseases. The aim of the present study was to draw correlations between clinical features,
treatment with chemotherapy and injury phenotypes and assess the impact of each upon perioperative
morbidity.
Patients and methods: Retrospective samples (n = 232) were scored grading steatosis, steatohepatitis
and sinusoidal injury (SI). Clinical data were retrieved from medical records. Correlations were drawn
between injury, clinical features and perioperative morbidity.
Results: Injury rates were 18%, 4% and 19% for steatosis, steatohepatitis and SI, respectively. High-
grade steatosis was more common in patients with diabetes [odds ratio (OR) = 3.33, P = 0.01] and patients
with a higher weight (OR/kg = 1.04, P = 0.02). Steatohepatitis was increased with metabolic syndrome
(OR = 5.88, P = 0.02). Chemotherapy overall demonstrated a trend towards an approximately doubled risk
of high-grade steatosis and steatohepatitis although not affecting SI. However, pre-operative chemo-
therapy was associated with an increased SI (OR = 2.18, P = 0.05). Operative morbidity was not increased
with chemotherapy, but was increased with steatosis (OR = 2.38, P = 0.02).
Conclusions: Diabetes and higher weight significantly increased the risk of steatosis, whereas meta-
bolic syndrome significantly increased risk of steatohepatitis. The presence of high-grade steatosis
increases perioperative morbidity, not administration of chemotherapy per se.
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Introduction
Chemotherapy is being used with increasing frequency early in
the treatment of patients with colorectal liver metastases (CRLM),
even when these lesions are resectable.1 In addition to improved
progression-free survival after a subsequent hepatectomy,2
this treatment increases the potential for perioperative morbidity
and appears to be associated with a number of injury phenotypes
now collectively referred to as chemotherapy-induced hepatic
injuries (CIHI).3 CIHI is divided into two main groups:
(i) chemotherapy-associated fatty liver diseases [the spectrum
of which includes chemotherapy-associated simple steatosis
(CASS) and chemotherapy-associated steatohepatitis (CASH)]
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and (ii) sinusoidal injuries [including sinusoidal dilation and con-
gestion, sinusoidal obstruction syndrome, haemorrhagic centri-
lobular necrosis (HCN) and nodular regenerative hyperplasia
(NRH)].
Controversy exists as to the effect of chemotherapy on peri-
operative morbidity.4,5 Chemotherapy administration has not
always been demonstrated as an independent risk factor for the
development of post-operative complications, particularly in
countries with higher background rates of obesity (and subse-
quent hepatic steatosis).4 On the other hand, CASH has been
clearly associated with an increased perioperative mortality of
14.1% compared with 1.6% in those without steatohepatitis and is
seen with increased frequency in association with irinotecan.6
Chemotherapy regimens for adjuvant and neoadjuvant treat-
ment of colorectal carcinoma and CRLM consist of 5-flurouracil
(5-FU) in association with oxaliplatin (FOLFOX or XELOX if
capecitabine, the oral pro-drug of 5FU, is chosen) or 5-FU with
irinotecan (FOLFIRI). 5-FU does not appear to be specifically
associatedwith any injury phenotype other thanCASS (withwhich
oxaliplatin and irinotecan are also non-specifically associated).7
Oxaliplatin is associated with the development of sinusoidal
injuries.8 This injury phenotype is associated with an increased
rate of blood transfusion perioperatively,9 and increased morbid-
ity in general.10
Non-alcoholic fatty liver diseases (NAFLD) in general are
common, and phenotypically there is nothing differentiating
CASH from non-alcoholic steatohepatitis (NASH), or differenti-
ating CASS from simple steatosis secondary to obesity or diabetes,
other than the association with administration of chemothera-
peutics. This confounds attempts to ascribe risk to these chemo-
therapeutics specifically in terms of injury phenotype causation.
It is known that factors such as diabetes and obesity increase rates
of injuries such as steatosis.11 However, whether chemotherapy
exerts an independent additive effect remains to be definitively
demonstrated.
It is likely that the increased perioperative morbidity that some
have found in association with chemotherapy5 is actually second-
ary to a hepatic injury and not the chemotherapy as such. Addi-
tionally, the administration of chemotherapy that does not result
in injury development may not be associated with higher rates of
complications. These possibilities remain unproven.
In the present study, patient co-morbidity profile and chemo-
therapy administration are examined to separate out the compo-
nent effects of each of these factors in the development of hepatic
injury as seen histologically and to determine the effect of both
chemotherapy in general and CIHI, specifically, on post-operative
outcomes.
Patients and methods
Patients
Patients who had undergone a hepatectomy for any pathology
between September 2001 and November 2009 were identified
from the Victorian Cancer Biobank, Melbourne, Australia, a pro-
spectively collected tissue bank. Additional patients who had
undergone a hepatectomy for CRLM at The Alfred Hospital, Mel-
bourne between May 1995 and September 2009 were identified
from a database detailing these patient’s clinical and operative
outcomes. Clinical data relating to demographics, co-morbidities,
details of primary colorectal disease, chemotherapy administra-
tion (adjuvant after colorectal primary, and any treatment for
metastatic disease), as well as details of hepatic surgery including
post-operative course, were collected where available from previ-
ously collated databases, or retrieved from review of the clinical
history of identified patients.
Histological assessment
Haematoxylin and Eosin (H&E) slides of non-tumourous liver
were available for all patients, and Masson’s trichrome stains
were generated from formalin-fixed paraffin-embedded tissue
blocks containing non-tumourous liver from either the tissue
bank specimens or pathology archive. Both H&E and Masson’s
slides were independently and blindly scored for degree of ste-
atosis (high grade steatosis was defined as >33% fatty replace-
ment), non-alcoholic fatty liver disease activity score (NAS),12
portal fibrosis score, degree of sinusoidal dilation (high grade
defined as >1/3 of lobule involved)8 and presence or absence of
four other features of sinusoidal injury (fibrotic venular occlu-
sion, extravasated red blood cells, HCN and NRH). Steatohepa-
titis was diagnosed when steatosis was present at >5%, and the
NAS was >2. Batches of 25 slides were independently scored by
two pathologists, one from the Peter MacCallum Cancer Centre
(W.M.), the other from the The Alfred Hospital (A.P.), with one
observer present during all scoring (C.P.). A random sample of
25% of slides was independently and blindly scored twice by the
same pathologist to confirm intra-observer consistency. Inter-
observer consistency was also assessed and, where injury scores
from each pathologist were two or more points discrepant, con-
sensus was achieved by slide review with both pathologists and
observer following collation of all data. American Association for
the Study of Liver Diseases grade and stage13 were determined for
all slides designated as NASH.
Statistical analysis
Associations between injury types were assessed using Fisher’s
exact tests. Hierarchical logistic regression models were used to
assess the association of collected characteristics of samples with
the development of high-grade injury and perioperative morbid-
ity among all operations. These models tested the fixed effects of
the characteristics and accounted for effects of the patient unit by
adding patient as a random effect. Univariate and multiple vari-
able models were estimated using the PROC GLIMMIX
command in SAS (v9.2; SAS Institute Inc., Cary, NC, USA) using
the method ‘between/within’ for computing the denominator
degrees of freedom for tests of fixed effects. Spearman’s correla-
tion coefficient was used to quantify the agreement in injury grade
between the reviewers.
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Results
There were 221 patients, providing 232 samples (12 patients
having had 2 separate hepatic operations for recurrent CRLM in
that time period). More than half the patients (123/221) came
from the Alfred Hospital (with 50 patients contributed in the last
5 years of the study period), with the remainder from the Victo-
rian Cancer Biobank.
The median age of the cohort was 62 years (range 22–86) and
36% were female. From 232 samples, high-grade steatosis was
found in 18%, high-grade sinusoidal dilation in 19% and high-
grade steatohepatitis in 4% (Table 1). There was no association
between high-grade steatosis and steatohepatitis (Fisher’s
P-value = 0.07).
There was good inter- and intra-observer correlations on most
of the elements scored for hepatic injury (Table 2). Spearman’s
correlation co-efficients for steatosis were r = 0.84 (P < 0.0001)
and r = 0.92 (P < 0.0001) for inter- and intra-observer scores,
respectively. In particular, there were only four cases (2%) of ste-
atosis scoring where the two pathologists differed by more than
one point in terms of degree of steatosis. There was 100% agree-
ment within one point when the same pathologist scored steatosis
at two separate time points, and in 60 cases (97%) exactly the
same score was awarded on both occasions.
Agreement upon diagnosis of steatohepatitis was more prob-
lematic. The absence of steatohepatitis was agreed upon in 95% of
cases (212 of the 223 cases without steatohepatitis), but the pres-
ence of the disease was only initially independently agreed upon in
50% of cases (5 of the 10 cases).
Spearman’s correlation co-efficient for portal fibrosis, perisinu-
soidal fibrosis and lobular inflammation showed agreement that
was statistically significantly greater than would be expected by
chance (r = 0.39, 0.41, 0.39, respectively); however,Mallory bodies
and hepatocyte ballooning scoring only agreed at levels expected
by chance (r = -0.02, -0.10, respectively) (Table 2).
Regarding sinusoidal injury, there was lack of inter-observer
agreement in 14% of cases (32 cases where the score was
more than 1 point different); however, Spearman’s correlation
co-efficient for both inter- and intra-observer variation was con-
sistent with agreement more than expected by chance (Table 2).
Diabetes was associated with a higher rate of high-grade steato-
sis [odds ratio (OR) = 3.24, 95% confidence interval (CI) 1.36–
7.71, P = 0.01] and a lower rate of high-grade sinusoidal injury
(OR = 0.14, 95% CI 0.02–0.99, P = 0.02). Similarly, a body mass
index (BMI) >30 kg/m2 was associated with high-grade steatosis
(OR = 3.14, 95% CI 1.10–8.96, P = 0.05), and for each additional
kilogram there was an increase of 4% in the likelihood of
high-grade steatosis. Metabolic syndrome (a clinical syndrome
characterized by at least three features from hypertension,
hypertriglyceridaemia, low level high-density lipoprotein (HDL),
hyperglycaemia or central adiposity14) was associated with steato-
hepatitis (OR = 5.88, 95% CI 1.36–25.00, P = 0.02). Male gender
and hyper-cholesterolaemia were also associated with high-grade
steatosis (OR for male gender = 2.77, 95% CI 1.16–6.62, P = 0.03;
hypercholesterolaemia OR = 2.48, 95% CI 1.15–5.36, P = 0.03).
There were no other associations between patient co-morbidity
and injury phenotype.
Of those samples having exposure to chemotherapy (60.7% of
cohort, n = 133), one-third of the patients had received treatment
within 2 months of hepatic resection (n = 46) and 7.5% of
the patients had been treated with chemotherapy twice, first for
the colorectal primary, then again for CRLM (n = 10). Given the
retrospective nature of the cohort, the data relating to duration of
treatment with chemotherapy was poor. Just fewer than half the
cohort had available data in this regard (49.6%). The average
number of cycles of chemotherapy administered for treatment of
the colorectal primary was 8.0 (median 6.0, range 1–26), and for
hepatic metastases prior to hepatectomy, the average and median
was 6.0 cycles (range 1–12). Analysis of injury type according to
cycle number was not undertaken given the large gaps in these
data.
The rates of steatosis and steatohepatitis were higher in those
having any chemotherapy compared with those never exposed at
20% vs. 12% and 5% vs. 2%, respectively, although these differ-
ences did not reach statistical significance (Table 3). The rate of
sinusoidal injury was not higher overall in patients treated with
any chemotherapy, however, pre-operative treatment was associ-
ated with an increased risk of high-grade sinusoidal injury
compared with patients who did not receive chemotherapy
pre-operatively (OR = 2.18, 95% CI 1.01–4.74, P = 0.05).
When controlling for diabetes, a BMI >30 kg/m2 or metabolic
syndrome, the development of steatosis still has an OR of approxi-
Table 1 Prevalence of hepatic injury in a cohort of 232 hepatic resec-
tion samples
Injury Definition Per cent (n)
Steatosis
Grade 0 0% 24% (56)
1 >0–5% 31% (73)
2 >5–33% 27% (63)
3 >33–66% 12% (27)
4 >66% 6% (14)
Sinusoidal injury
Grade 0 Nil 70% (163)
1 up to 1/3 lobular involvement 11% (26)
2 >1/3–2/3 lobular involvement 10% (23)
3 >2/3 to complete lobular involvement 9% (21)
Steatohepatitis
Presence steatosis >5%, NAFLD activity
scorea >2
4% (10)
aNAFLD activity score (NAS) = sum of score for Mallory bodies, lobular
inflammation, hepatocyte ballooning and perisinusoidal fibrosis (each
factor scored 0 = absent, 1 = focal involvement of some lobules, 2 = focal
involvement of most lobules, 3 = focal involvement of most or all, with
diffuse involvement of some or most).12
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mately 2.0 with administration of chemotherapy, although
because of the small sample size, the CIs cross unity (Fig. 1). This
suggests the effect of chemotherapy upon development of injury
is independent of the effect these co-morbidities have in increas-
ing the rate of injury. That is, chemotherapy is a factor increasing
the rate of steatosis independent of co-morbidities which also
increase the rate of steatosis.
There were 331 discrete operative procedures carried out
during 230 operations for which data are available (some patients
have multiple procedures such as resection of multiple separate
segments of liver during one operation). This includes 21 repeat
hepatectomies (of which 12 patients have tissue available for
analysis). There was no surgical data for 11 patients for whom
tissue was available. Portal vein embolization was employed pre-
operatively in two patients.
Of these procedures, 139 (60.4%) were considered major
hepatic resections (removing three or more hepatic segments) and
the remaining 91 were minor hepatic resections (Table 4). The
distribution of hepatic injuries between major and minor resec-
tions was equivalent. Perioperative morbidity was higher in
patients undergoing a major resection (41% vs. 28%, Table 5),
although this failed to reach statistical significance (Fig. 2).
The rate of operative morbidity in the cohort overall was 36%
(95% CI 29%–42%), not varying with or without the administra-
tion of chemotherapy (37% vs. 38%) (Table 5 and Fig. 2). Major
morbidity included post-operative bile leak [8% (5%–12%)],
hepatic failure [1% (0%–3%)] and three patients returning to
theatre for bleeding [1% (0%–4%)]. There were two deaths
[mortality = 1% (0%–3%)].
There were 150 separate complications which either required
treatment, or prolonged inpatient stay, documented for 83
patients from the 230 episodes where perioperative morbidity
data were available. Although the Clavien–Dindo system15 was not
retrospectively applied to the complications that were retrieved
from the medical notes, by definition there were no Grade I com-
plications recorded. The median number of complications per
patient was one (range 1–9). There were 43 patients who suffered
one complication, 25 who suffered two complications and 15 who
suffered three or more complications. There were also 14 patients
who were readmitted within 30 days, although one of these
patients readmissions was for a planned lung resection, and
another was readmitted to have a further disc of diaphragm
excised after a pathology report documented an incomplete
margin on the diaphragm that had been excised at the first
Table 2 Inter- and intra-observer variation in scoring of hepatic injuries in a cohort of 232 hepatic resection samples
Parameter Pathologist A.P. vs. pathologist W.M. Pathologist A.P. 1st score vs. 2nd score
n Spearman's correlation
co-efficient (P-value)
n Spearman's correlation
co-efficient (P-value)
Steatosis 232 0.84 (<0.0001) 62 0.92 (<0.0001)
Steatohepatitis
Portal fibrosis 226 0.39 (<0.0001) 62 0.55 (<0.0001)
Perisinusoidal fibrosis 226 0.41 (<0.0001) 62 0.74 (<0.0001)
Lobular inflammation 232 0.39 (<0.0001) 62 0.56 (<0.0001)
Mallory bodies 232 -0.02 (0.82) 62 1.0 (<0.0001)
Hepatocyte ballooning 232 -0.10 (0.13) 62 0.33 (0.009)
Sinusoidal injury (SI) 232 0.53 (<0.0001) 62 0.52 (<0.0001)
Other SI features
NRH 232 0.28 (<0.0001) 62 0.46 (<0.0001)
Extravasated RBC 232 0.3 (<0.0001) 62 (not estimated)
HCN 232 -0.02 (0.79) 62 1.0 (<0.0001)
SI, sinusoidal injury; NRH, nodular regenerative hyperplasia; RBC, red blood cells; HCN, haemorrhagic centrilobular necrosis.
Table 3 Chemotherapy exposure and rate of injury among 218 patients undergoing hepatic resection
Chemotherapy exposure Number of samples Steatosis (>33%) Steatohepatitis Sinusoidal injury
(>1/3 lobule)
Never 85 12% [6%–21%]a 2% [0%–8%]b 19% [11%–29%]
Any 133 20% [14%–28%]a 5% [2%–11%]b 19% [13%–27%]
Preoperatively 46 20% [9%–34%] 4% [1%–15%] 33% [20%–48%]c
Once only (but not preoperatively) 56 20% [10%–33%] 9% [3%–20%] 15% [6%–27%]c
aOdds ratio (OR) = 1.90 [95% confidence interval (CI) 0.87–4.17, P = 0.14].
bOR = 2.30 (95% CI 0.47–11.33, P = 0.49).
cOR = 2.18 (95% CI 1.01–4.74, P = 0.05).
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operation, and so therefore neither of these strictly represent peri-
operative complications.
Respiratory complications account for 30.7% of all the compli-
cations (46 separate complications), while 28% of the overall
complications are hepatobiliary specific (42 episodes). The
remainder were accounted for by general complications (62 epi-
sodes, 41.3%). There were 29, 31 and 47 patients affected by
respiratory, hepatobiliary and general complications, and as such
the rate of these complications in the cohort was 13%, 14% and
21%, respectively. Overall, 36% of patients suffered at least one
complication during their post-operative course.
Pneumonia and pleural effusion account for over three-
quarters of all respiratory complications (20 and 16 cases, respec-
tively, Fig. 3a) and for 13.3% and 10.7% of complications overall.
The majority of hepatobiliary complications were bile leak and
subphrenic collection requiring intervention (18 and 14 cases
respectively), again accounting for more than three-quarters of
the complications in that subgroup (Fig. 3b). Bile leak and sub-
phrenic collection represented 12.0% and 9.3% of compli-
cations overall. The commonest general complications were
arrhythmia (13 cases, 8.7% of overall complications) and the
requirement for a blood transfusion (11 cases, 7.3% of overall
complications) (Fig. 3c).
Overall morbidity was higher among patients if their sample
showed evidence of high-grade steatosis (OR = 2.50, 95% CI
1.20–5.23, P = 0.02; Table 5), with a larger effect seen in the sub-
group of general medical perioperative morbidity (OR = 3.08,
95% CI 1.45–6.54, P = 0.004). There was a higher rate of respira-
tory complications with higher grades of steatosis (increasing
from 7.7% in those with grade 0 steatosis to 21.4% in those
with grade 4 steatosis), although the hepatobiliary-specific peri-
operative morbidity subgroup did not demonstrate a statistically
significant increase in the rate of morbidity with high-grade ste-
atosis. The largest numerical increase was in the rate of wound
infections in those with high-grade steatosis [5 wound infections
in 39 patients with high-grade steatosis (13.0%) vs. 5 wound
infections in 193 patients without high-grade steatosis (2.6%),
P = 0.02]. The presence of sinusoidal injury or steatohepatitis and
the administration of chemotherapy were not associated with
increased morbidity.
Discussion
Injury patterns are common tissue-based responses
Phenotypically, the liver manifests injury in a limited number of
ways.16 Steatosis is a common end result of many injurious agents,
Diabetes (n = 27)
OR (95% CI) for steatosis
No diabetes (n = 188)
BMI ≥ 30kg/m2 (n = 20)
BMI < 30kg/m2 (n = 110)
metabolic syndrome (n = 18)
No metabolic syndrome (n = 192)
All (n = 219)
0.5 1.0 2.0 5.0 10 20 40
Missing (diabetes status), n = 4
Missing (BMI status), n = 89
Missing (metabolic syndrome), n = 9
Figure 1 Odds ratio (OR) for developing steatosis when chemotherapy is administered in the presence or absence of diabetes, elevated
body mass index (BMI) or metabolic syndrome. The effect of chemotherapy can be seen to be independent of the co-morbidity. For all
patients, the OR for steatosis when administered chemotherapy is displayed as the diamond at the bottom of the diagram
Table 4 Operative intervention in cohort
Procedure % (n)
Right hepatectomy 23.3 (77)
Extended right hepatectomy 7.6 (25)
Right posterior sectionectomy 2.4 (8)
Central heptatectomy 0.6 (2)
Left hepatectomy 5.1 (17)
Extended left hepatectomy 1.5 (5)
Left lateral sectionectomy 9.7 (32)
Formal segmentectomy 14.5 (48)
Wedge resection 32.0 (106)
Intra-operative hepatic ablation 3.3 (11)
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ranging from drugs to chronically elevated blood lipids.17
Steatohepatitis results from oxidative stress acting upon an
already steatotic liver.18 These injuries can be induced by chemo-
therapy but are also associated with other risk factors such as
obesity, diabetes and metabolic syndrome.19 This may confound
analyses comparing patients administered chemotherapy with
those not treated, as there will be a background rate of steatosis
in the non-chemotherapy group, potentially obscuring the
ability to detect increases in rates of steatosis secondary to
chemotherapeutic treatment.
Diabetes, obesity and metabolic syndrome increase
rates of simple steatosis and/or steatohepatitis
We have confirmed established associations between diabetes,
weight and metabolic syndrome with steatosis and steatohepatitis
in our cohort overall (OR = 3.24 and 1.04 with respect to steatosis
for diabetes and higher weight per kg respectively, and OR = 5.88
with respect to steatohepatitis and metabolic syndrome). Clini-
cally, these are highly significant increases in the risk of developing
these injury patterns, and are independent of chemotherapy
administration. When chemotherapy is administered, there is a
suggested independent effect with an OR of approximately two for
all of these injury patterns over and above that inferred from the
co-morbidity itself [OR for steatosis 1.90 (0.87–4.17), for steato-
hepatitis 2.30 (0.47–11.33)]. That is, in both those with and
without co-morbidity, chemotherapy appears to increase the rate
of steatosis and steatohepatitis independent of comorbidity. The
ability to demonstrate this with statistical significance was limited
by the small sample size and the CIs therefore cross unity, this is an
inherent limitation in fixed-number retrospective cohorts such as
Table 5 Rate of perioperative morbidity according to the presence or absence of hepatic injury and chemotherapy exposure
Parameter n Rate of morbidity when
present
Rate of morbidity when
absent
OR for morbidity (95% CI) P-value
High-grade steatosis 223 51% (20/39) 30% (37/125) 2.50 (1.20–5.23) 0.02
High-grade steatohepatitis 223 50% 35% 1.85 (0.50–6.67) NS
High-grade sinusoidal injury 223 32% 36% 0.82 (0.39–1.85) NS
Major vs. minor resection 221 41% 28% 1.78 (0.99–3.19) NS
Chemotherapy 214 37% 38% 1.11 (0.62–2.00) NS
Oxaliplatin 169 41% 35% 1.32 (0.63–2.78) NS
5-Flurouracil 173 40% 35% 1.28 (0.68–2.44) NS
OR, odds ratio; CI, confidence interval; NS, non-significant.
OR (95% CI) for morbidity
0.5 1.0 2.0 5.0 10 20 40
Steatosis (n = 223)
Steatohepatitis (n = 223)
Sinusoidal injury (n = 223)
Any Injury pattern (n = 223)
Major resection (n = 221)
Oxaliplatin (n = 169)
Flurouracil (n = 173)
Figure 2 Odds ratio (OR) for perioperative morbidity amongst patients with or without hepatic injury, and in those administered chemo-
therapy. Only those patients with steatosis had a statistically significantly increased risk of perioperative morbidity [OR = 2.50, 95%
confidence interval (CI) 1.20–5.23, P = 0.02]. Note that major vs. minor resection was associated with a higher rate of perioperative morbidity,
with an OR = 1.78 that almost reached statistical significance (95% CI 0.99–3.19, P = 0.06)
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this. Our cohort size had approximately 80% power to detect
an association with injury for a factor of prevalence of about
15% and with an OR of 2.85 with a significance level of
a = 0.05. There appeared to be no difference in the rate of sinu-
soidal injury comparing patients administered chemotherapy
overall compared with no chemotherapy, in spite of others having
demonstrated an association.8 Nevertheless there was a statisti-
cally significantly higher rate of sinusoidal injury seen when
chemotherapy was administered in the pre-operative setting
(OR = 2.18).
Hepatic injury presence increases the rate of
perioperative morbidity
The ability to demonstrate increased perioperative morbidity sec-
ondary to chemotherapy2,9,20 is similarly confounded in the litera-
ture. This may be because there are high rates of injuries such as
steatosis in those not administered chemotherapy in some cohorts,
obscuring the ability to detect the effect of chemotherapy. Equally,
not all patients developCIHI,and those that donotdevelophepatic
injury should not be at higher risk of perioperative morbidity. The
EORTC 409832 trial did demonstrate increased perioperativemor-
bidity in the group treated with pre-operative chemotherapy,
although this was not stratified by the presence or absence of CIHI.
We have observed no increase in perioperative morbidity in those
administered chemotherapy as a whole, but have shown that those
who display high-grade steatosis are at an increased risk of mor-
bidity. Thus it may be concluded that it is the development of
hepatic injury (be it from chemotherapy, obesity, diabetes ormeta-
bolic syndrome) that predisposes to perioperative morbidity, not
the administration of chemotherapy as such.
A
B
C
Figure 3 Perioperative morbidity. For each of the main groups of perioperative morbidity: (a) respiratory; (b) hepatobiliary specific; and (c)
general complications, the proportion of each category that each individual disease process represents is displayed. ERCP req, endoscopic
retrograde cholangiopancreatography required; Subphrenic, subphrenic collection requiring treatment intervention; NSTEMI, non-ST eleva-
tion myocardial infarction; DVT, deep venous thrombosis; Abi, antibiotics
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Prediction of CIHI could lower perioperative morbidity
Concerns about inferior outcomes in patients subjected to a hepa-
tectomy after chemotherapy should really be restated to acknowl-
edge that inferior outcomes are more likely to be seen in those
who develop or have liver injury. Efforts should therefore centre
on establishing who is at risk of damage from chemotherapy and
avoiding treatment in those patients, rather than abandoning che-
motherapy pre-operatively altogether. Identifying patients at high
risk of developing injury before treatment commences remains
the goal. Clearly some patients, such as younger females without
diabetes or hypercholesterolaemia, are less likely to a have pre-
existing injury and may therefore be more likely to tolerate
therapy well. Patients who do not develop CIHI can therefore
expect to enjoy the improvements in progression-free survival
that have been demonstrated2 without fear of increased peri-
operative morbidity secondary to hepatic injury. Similarly,
patients who do develop CIHI must be identified as quickly as
possible so their treatment can be altered accordingly.
Conclusion
The presence of hepatic injury increases perioperative morbidity
regardless of the cause of injury. Chemotherapy may increase the
rate over and above the increase seen from comorbidities such as
diabetes and obesity in some patients. The pre-treatment identi-
fication of which patients will develop injury in response to che-
motherapy would be extremely useful in avoiding toxic therapies
in those patients, while not denying the improvements pre-
operative treatment may have in those that are not likely to
develop CIHI as a result.
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